Medtronic's revenue growth has accelerated to 13.7% year-over-year in Q1 FY2027, suggesting its portfolio optimization strategy is gaining traction. However, this growth is accompanied by significant margin volatility and erratic cash conversion, with operatin...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 13.7% year-over-year in Q1 FY2027, but operating margin remains constrained at 18.1% due to elevated SG&A spending of $3.2B (33% of revenue), suggesting growth investments are currently offsetting scale benefits.
Medtronic is a global leader in medical technology, services, and solutions, collaborating to address healthcare challenges.
Medtronic's strong competitive positioning and wide moat support its long-term business resilience and growth.
The company's innovation pipeline, including products like the Stealth AXiS surgical system, drives future growth opportunities.
Trailing total returns as of 10/11/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 1, 2026 | $1.45+4.3% vs $1.39 | $9.8B+2.2% vs $9.5B |
Q3 2026 Jun 3, 2026 | $1.55+0.6% vs $1.54 | $9.8B+1.9% vs $9.6B |
Q1 2026 Feb 17, 2026 | $1.36+1.5% vs $1.34 | $9.0B+1.2% vs $8.9B |
Q4 2025 Nov 18, 2025 | $1.36+3.8% vs $1.31 | $9.0B+1.1% vs $8.9B |
Medtronic struggled with macro, operational, and forex headwinds in recent years. But its business is recovering, and it's on track to become a Dividend King next year.
A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
GALWAY, Ireland, Oct. 7, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced the final exchange ratio for its previously announced offer to exchange outstanding Medtronic ordinary shares for shares of common stock of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). Medtronic is offering to exchange up to 225,361,295 shares of MiniMed common stock for outstanding Medtronic ordinary shares in the exchange offer and, if the exchange offer is oversubscribed, Medtronic currently intends to exchange all of Medtronic's remaining interest in MiniMed (an additional 27,452,053 shares of MiniMed common stock), without extending the exchange offer period.
Benchmark MDT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Medtronic plc (MDT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $88.48 | $113.6B | 23.72 | 8.43% | 13.2% | 9.76% | 3.19% | |
| $99.60 | $173.48B | 26.77 | 5.67% | 13.91% | 12.09% | — | |
| $42.73 | $63.51B | 22.03 | 19.87% | 17.47% | 14.76% | — | |
| $85.21 | $49.06B | 46.56 | 11.55% | 15.43% | 9.66% | — | |
| $277.33 | $106.32B | 33.02 | 11.16% | 14.43% | 16.36% | — | |
| $89.14 | $17.25B | 25.11 | 7.2% | 9.48% | 6.36% | — |
Medtronic plc (MDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Medtronic plc (MDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 1, 2026·SEC
Jun 3, 2026·SEC
May 18, 2026·SEC
Get notified when MDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Medtronic plc (MDT) stock FAQ — growth, dividends, profitability & financials explained
Medtronic plc (MDT) reported $37.54B in revenue for fiscal year 2026. This represents a 1440% increase from $2.44B in 1997.
Medtronic plc (MDT) grew revenue by 8.4% over the past year. This is steady growth.
Yes, Medtronic plc (MDT) is profitable, generating $5.23B in net income for fiscal year 2026 (13.2% net margin).
Yes, Medtronic plc (MDT) pays a dividend with a yield of 3.19%. This makes it attractive for income-focused investors.
Medtronic plc (MDT) has a return on equity (ROE) of 9.8%. This is below average, suggesting room for improvement.
Medtronic plc (MDT) generated $6.13B in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
